Methicillin-resistant Staphylococcus aureus (MRSA) continues to cause significant morbidity and mortality. Despite advances in medical care, the prevalence of both community-acquired and hospital-acquired MRSA has progressively increased. Community-acquired MRSA typically occurs in patients without recent illness or hospitalization, presents as acute skin and soft tissue infections, and is usually not multidrug resistant. Hospital-acquired MRSA, however, presents in patients recently hospitalized or treated in long-term care settings and in those who have had medical procedures and is usually associated with multidrug-resistant strains. Both types of infections, if not properly treated, have the potential to become invasive. This article discusses current intravenous antibiotics that are available for the empiric treatment of MRSA infections along with a newer phenomenon known as the “seesaw effect.”
Skip Nav Destination
Article navigation
1 July 2015
Symposium Infectious Disease|
July 01 2015
Intravenous Antibiotics Used in the Treatment of Methicillin-Resistant Staphylococcus Aureus
Kristine Anne Scordo, RN, PhD, ACNP-BC
Kristine Anne Scordo, RN, PhD, ACNP-BC
Kristine Anne Scordo is Professor and Director, Adult-Gerontology Acute Care Nurse Practitioner Program, College of Nursing, Wright State University, Dayton, OH 45435 (kscordo@cinci.rr.com).
Search for other works by this author on:
AACN Adv Crit Care (2015) 26 (3): 233–243.
Citation
Kristine Anne Scordo; Intravenous Antibiotics Used in the Treatment of Methicillin-Resistant Staphylococcus Aureus. AACN Adv Crit Care 1 July 2015; 26 (3): 233–243. doi: https://doi.org/10.4037/NCI.0000000000000095
Download citation file:
Sign in
Don't already have an account? Register
AACN Account
Sign InSign in via your Institution
Sign in via your InstitutionShort-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access
15
Views